Abstract
Thirty-two patients with measurable metastatic colorectal cancer refractory to 5-fluorouracil-containing regimens received PCNU (1-(2-chloroethyl)-3-3(2,6-dioxo-3-piperidyl)-1-nitrosourea NSC 95466) on a single-day I.V. schedule administered every 6 weeks. Good-risk patients received PCNU at the starting dose of 100 mg/m2, while patients who had received radiotherapy or myelosuppressive drugs such as mitomycin C received an initial dose of 75 mg/m2. There were two partial remissions. Fifteen patients including four with minor tumor regression had disease stabilization. The dose-limiting toxicity was myelosuppression, with thrombocytopenia being more severe than neutropenia. The myelosuppression occurred late in the treatment cycle (days 25-32), was more severe with repeated treatments, and was more severe in patients who had a poor bone marrow reserve. Other toxicities were mild and infrequent. PCNU administered by the single-dose I.V. schedule as used in this study has very modest antitumor activity against colorectal cancer in humans.
Original language | English (US) |
---|---|
Pages (from-to) | 49-52 |
Number of pages | 4 |
Journal | Unknown Journal |
Volume | 6 |
Issue number | 1 |
DOIs | |
State | Published - 1983 |
ASJC Scopus subject areas
- Oncology
- Cancer Research